![]() |
Name |
Paspalitrem C
|
Molecular Formula | C32H39NO4 | |
IUPAC Name* |
(1S,4R,5S,16S,19S,23R)-19-hydroxy-4,5,24,24-tetramethyl-12-(3-methylbut-2-enyl)-25,26-dioxa-7-azaheptacyclo[21.2.1.01,20.04,19.05,16.06,14.08,13]hexacosa-6(14),8,10,12,20-pentaen-22-one
|
|
SMILES |
CC(=CCC1=C2C3=C([C@]4([C@H](C3)CC[C@@]5([C@@]4(CC[C@]67C5=CC(=O)[C@H](O6)C(O7)(C)C)C)O)C)NC2=CC=C1)C
|
|
InChI |
InChI=1S/C32H39NO4/c1-18(2)10-11-19-8-7-9-22-25(19)21-16-20-12-13-31(35)24-17-23(34)27-28(3,4)37-32(24,36-27)15-14-29(31,5)30(20,6)26(21)33-22/h7-10,17,20,27,33,35H,11-16H2,1-6H3/t20-,27-,29+,30+,31+,32-/m0/s1
|
|
InChIKey |
MXOIVWLOTRYIQC-TZHHUJIHSA-N
|
|
Synonyms |
Paspalitrem C; 4-(3-Methyl-2-butenyl)paspalinine; 44ZSF8JL8Y; 90866-61-8; 4H-3,15A-EPOXY-1-BENZOXEPINO(6',7':6,7)INDENO(1,2-B)INDOL-4-ONE, 2,3,5B,6,7,7A,8,13,13B,13C,14,15-DODECAHYDRO-5B-HYDROXY-2,2,13B,13C-TETRAMETHYL-9-(3-METHYL-2-BUTENYL)-, (3R,5BS,7AS,13BS,13CR,15AS)-
|
|
CAS | 90866-61-8 | |
PubChem CID | 9848881 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 501.7 | ALogp: | 5.1 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 71.6 | Aromatic Rings: | 7 |
Heavy Atoms: | 37 | QED Weighted: | 0.5 |
Caco-2 Permeability: | -4.783 | MDCK Permeability: | 0.00001980 |
Pgp-inhibitor: | 0.95 | Pgp-substrate: | 0.105 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.146 |
Blood-Brain-Barrier Penetration (BBB): | 0.968 | Plasma Protein Binding (PPB): | 95.23% |
Volume Distribution (VD): | 2.733 | Fu: | 4.42% |
CYP1A2-inhibitor: | 0.117 | CYP1A2-substrate: | 0.986 |
CYP2C19-inhibitor: | 0.763 | CYP2C19-substrate: | 0.815 |
CYP2C9-inhibitor: | 0.596 | CYP2C9-substrate: | 0.057 |
CYP2D6-inhibitor: | 0.621 | CYP2D6-substrate: | 0.125 |
CYP3A4-inhibitor: | 0.914 | CYP3A4-substrate: | 0.938 |
Clearance (CL): | 12.865 | Half-life (T1/2): | 0.043 |
hERG Blockers: | 0.397 | Human Hepatotoxicity (H-HT): | 0.734 |
Drug-inuced Liver Injury (DILI): | 0.224 | AMES Toxicity: | 0.32 |
Rat Oral Acute Toxicity: | 0.956 | Maximum Recommended Daily Dose: | 0.953 |
Skin Sensitization: | 0.846 | Carcinogencity: | 0.967 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
Respiratory Toxicity: | 0.987 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001967 | ![]() |
0.807 | D06YFA | ![]() |
0.261 | ||
ENC002359 | ![]() |
0.552 | D02IQY | ![]() |
0.240 | ||
ENC003875 | ![]() |
0.545 | D0Q0PR | ![]() |
0.240 | ||
ENC002168 | ![]() |
0.530 | D06IIB | ![]() |
0.230 | ||
ENC003876 | ![]() |
0.440 | D04GJN | ![]() |
0.230 | ||
ENC001492 | ![]() |
0.439 | D0W6DG | ![]() |
0.229 | ||
ENC000836 | ![]() |
0.433 | D02JNM | ![]() |
0.225 | ||
ENC002013 | ![]() |
0.429 | D0V4WD | ![]() |
0.223 | ||
ENC003929 | ![]() |
0.413 | D0V3ZA | ![]() |
0.222 | ||
ENC003329 | ![]() |
0.397 | D01TSI | ![]() |
0.222 |